WFS1_HUMAN,M632I,0.095,-,-,-
WFS1_HUMAN,A741T,0.071,-,-,-
WFS1_HUMAN,A787T,0.064,-,-,-
WFS1_HUMAN,D788N,0.044,-,-,-
WFS1_HUMAN,I296S,0.708,Altered Transmembrane protein (Pr = 0.35 | P = 1.9e-05); Gain of Helix (Pr = 0.28 | P = 0.03); Altered Stability (Pr = 0.14 | P = 0.02), None,-
WFS1_HUMAN,L432R,0.944,Altered Metal binding (Pr = 0.28 | P = 0.02); Altered Transmembrane protein (Pr = 0.15 | P = 0.01), ELME000333|ELME000335|PS00005,-
WFS1_HUMAN,R859P,0.821,Loss of Helix (Pr = 0.28 | P = 0.02); Altered Transmembrane protein (Pr = 0.20 | P = 5.3e-03), ELME000102|ELME000108|ELME000146|ELME000155|PS00005,-
WFS1_HUMAN,F770C,0.856,Altered Metal binding (Pr = 0.31 | P = 0.02); Altered DNA binding (Pr = 0.22 | P = 0.02); Loss of Acetylation at K768 (Pr = 0.21 | P = 0.04); Gain of Disulfide linkage at C765 (Pr = 0.14 | P = 0.04), ELME000233,-
WFS1_HUMAN,F439C,0.821,Altered Ordered interface (Pr = 0.25 | P = 0.02), ELME000053|ELME000336,-
WFS1_HUMAN,T461P,0.669,Altered Transmembrane protein (Pr = 0.31 | P = 1.2e-04), ELME000106|ELME000147|ELME000248,-
WFS1_HUMAN,T699M,0.761,Altered Transmembrane protein (Pr = 0.32 | P = 6.3e-05); Altered Ordered interface (Pr = 0.29 | P = 0.03); Loss of Allosteric site at W700 (Pr = 0.25 | P = 0.01); Altered Metal binding (Pr = 0.22 | P = 0.05); Altered DNA binding (Pr = 0.22 | P = 0.02), ELME000062|ELME000137,-
WFS1_HUMAN,L557F,0.255,-,-,-
WFS1_HUMAN,E830A,0.777,Altered Transmembrane protein (Pr = 0.34 | P = 5.4e-05); Loss of Strand (Pr = 0.26 | P = 0.04), ELME000220|PS00006,-
WFS1_HUMAN,G780R,0.839,Altered Transmembrane protein (Pr = 0.15 | P = 0.02), ELME000147|ELME000155|ELME000336|PS00005|PS00008,-
WFS1_HUMAN,H766Y,0.782,Altered Metal binding (Pr = 0.64 | P = 1.6e-03); Gain of Helix (Pr = 0.28 | P = 0.02); Gain of Loop (Pr = 0.28 | P = 0.01); Gain of Acetylation at K768 (Pr = 0.28 | P = 5.8e-03); Altered DNA binding (Pr = 0.22 | P = 0.02); Gain of Disulfide linkage at C765 (Pr = 0.10 | P = 0.05), ELME000182,-
WFS1_HUMAN,W540G,0.895,Altered Ordered interface (Pr = 0.32 | P = 3.4e-03); Loss of Helix (Pr = 0.27 | P = 0.05), PS00008,-
WFS1_HUMAN,C690R,0.962,Altered Metal binding (Pr = 0.49 | P = 4.0e-03); Altered Transmembrane protein (Pr = 0.36 | P = 1.9e-05); Gain of Catalytic site at C690 (Pr = 0.28 | P = 2.1e-03); Gain of Helix (Pr = 0.27 | P = 0.04); Gain of Relative solvent accessibility (Pr = 0.24 | P = 0.04); Loss of Disulfide linkage at C690 (Pr = 0.23 | P = 0.01); Gain of Allosteric site at C690 (Pr = 0.19 | P = 0.05), ELME000052|ELME000064,-
WFS1_HUMAN,I349K,0.782,Altered Ordered interface (Pr = 0.24 | P = 0.03); Altered Transmembrane protein (Pr = 0.22 | P = 3.6e-03), None,-
WFS1_HUMAN,R457G,0.728,Loss of Helix (Pr = 0.38 | P = 8.8e-05); Gain of Strand (Pr = 0.32 | P = 5.4e-04); Altered Ordered interface (Pr = 0.26 | P = 0.01); Altered Transmembrane protein (Pr = 0.25 | P = 1.6e-03); Gain of Sulfation at Y454 (Pr = 0.01 | P = 0.05), ELME000102|ELME000108|ELME000146|ELME000182|PS00005|PS00008,-
WFS1_HUMAN,P724S,0.890,Altered Transmembrane protein (Pr = 0.27 | P = 6.3e-04); Altered Disordered interface (Pr = 0.27 | P = 0.04); Gain of Helix (Pr = 0.27 | P = 0.04); Altered Metal binding (Pr = 0.24 | P = 0.02), None,-
WFS1_HUMAN,R375C,0.563,Altered Transmembrane protein (Pr = 0.34 | P = 5.4e-05), ELME000079|ELME000146|ELME000220,-
WFS1_HUMAN,Y528H,0.832,Altered Ordered interface (Pr = 0.30 | P = 4.6e-03); Altered Transmembrane protein (Pr = 0.27 | P = 5.7e-04); Altered DNA binding (Pr = 0.15 | P = 0.04), ELME000120|ELME000182|ELME000336,-
WFS1_HUMAN,C505Y,0.751,Altered Ordered interface (Pr = 0.30 | P = 2.7e-03); Altered Transmembrane protein (Pr = 0.13 | P = 0.02); Loss of N-linked glycosylation at N500 (Pr = 0.07 | P = 0.02), ELME000182,-
WFS1_HUMAN,Y110N,0.776,Loss of Acetylation at K108 (Pr = 0.24 | P = 0.02); Loss of Phosphorylation at Y110 (Pr = 0.24 | P = 0.05); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), ELME000120|ELME000182,-
WFS1_HUMAN,D171N,0.204,-,-,-
WFS1_HUMAN,S430W,0.858,Altered Ordered interface (Pr = 0.26 | P = 0.01); Altered Transmembrane protein (Pr = 0.24 | P = 1.5e-03), ELME000007|ELME000335,-
WFS1_HUMAN,W639G,0.805,Loss of Helix (Pr = 0.30 | P = 8.1e-03); Gain of Strand (Pr = 0.27 | P = 0.02); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), ELME000052|ELME000333,-
WFS1_HUMAN,A761V,0.272,-,-,-
WFS1_HUMAN,G736D,0.936,Altered Metal binding (Pr = 0.54 | P = 3.8e-03); Gain of Helix (Pr = 0.28 | P = 0.03); Altered Transmembrane protein (Pr = 0.27 | P = 8.2e-04); Altered Ordered interface (Pr = 0.24 | P = 0.04); Loss of Disulfide linkage at C733 (Pr = 0.17 | P = 0.03); Gain of Sulfation at Y739 (Pr = 0.02 | P = 0.04), ELME000081|ELME000301|PS00007,-
WFS1_HUMAN,L672P,0.878,Altered Ordered interface (Pr = 0.35 | P = 3.6e-03); Altered Transmembrane protein (Pr = 0.34 | P = 4.9e-05); Gain of Disulfide linkage at C673 (Pr = 0.21 | P = 0.02), ELME000005|ELME000120|ELME000155,-
WFS1_HUMAN,H323R,0.651,Altered Transmembrane protein (Pr = 0.18 | P = 8.3e-03), ELME000052|ELME000148|ELME000149|ELME000254|PS00005,-
WFS1_HUMAN,L382P,0.772,Altered Transmembrane protein (Pr = 0.32 | P = 1.0e-04), ELME000045|ELME000047|ELME000052|ELME000335,-
WFS1_HUMAN,L511P,0.939,Altered Ordered interface (Pr = 0.26 | P = 0.02); Altered Transmembrane protein (Pr = 0.18 | P = 8.7e-03), ELME000020|ELME000081|ELME000083|ELME000120|ELME000182,-
WFS1_HUMAN,T321M,0.622,Gain of Helix (Pr = 0.27 | P = 0.05); Altered Transmembrane protein (Pr = 0.19 | P = 7.0e-03), ELME000052|ELME000053|ELME000148,-
WFS1_HUMAN,L432Q,0.879,Altered Metal binding (Pr = 0.28 | P = 0.02); Altered Transmembrane protein (Pr = 0.15 | P = 0.02), ELME000140|ELME000333|ELME000335,-
WFS1_HUMAN,G736S,0.898,Altered Metal binding (Pr = 0.26 | P = 0.03); Altered Transmembrane protein (Pr = 0.26 | P = 1.2e-03); Altered Ordered interface (Pr = 0.24 | P = 0.05); Gain of Disulfide linkage at C733 (Pr = 0.18 | P = 0.02), None,-
WFS1_HUMAN,S443R,0.716,Altered Ordered interface (Pr = 0.26 | P = 0.01); Gain of ADP-ribosylation at S443 (Pr = 0.20 | P = 0.04); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), ELME000052|ELME000063|ELME000106|ELME000336,-
WFS1_HUMAN,N721Y,0.809,Altered Disordered interface (Pr = 0.39 | P = 5.6e-03); Altered Ordered interface (Pr = 0.34 | P = 1.3e-03); Altered Transmembrane protein (Pr = 0.29 | P = 2.7e-04); Altered Metal binding (Pr = 0.23 | P = 0.02), ELME000063,-
WFS1_HUMAN,A806P,0.882,Gain of Intrinsic disorder (Pr = 0.33 | P = 0.03); Gain of Loop (Pr = 0.29 | P = 7.9e-03); Altered Metal binding (Pr = 0.16 | P = 0.03); Altered Stability (Pr = 0.15 | P = 0.02); Altered Transmembrane protein (Pr = 0.12 | P = 0.03), ELME000053|ELME000062|ELME000155|ELME000173|ELME000197,-
WFS1_HUMAN,V333I,0.029,-,-,-
WFS1_HUMAN,K193Q,0.296,-,-,-
WFS1_HUMAN,A602V,0.075,-,-,-
WFS1_HUMAN,L499F,0.542,Loss of Helix (Pr = 0.28 | P = 0.02); Gain of Strand (Pr = 0.28 | P = 0.01); Altered Transmembrane protein (Pr = 0.18 | P = 7.6e-03); Loss of N-linked glycosylation at N500 (Pr = 0.07 | P = 0.02), ELME000070|ELME000155|ELME000333|ELME000336,-
WFS1_HUMAN,G76V,0.115,-,-,-
WFS1_HUMAN,V779M,0.511,Gain of Intrinsic disorder (Pr = 0.32 | P = 0.03); Altered Transmembrane protein (Pr = 0.11 | P = 0.03), ELME000147|ELME000155|ELME000233|ELME000336,-
WFS1_HUMAN,A23T,0.103,-,-,-
WFS1_HUMAN,H67R,0.053,-,-,-
WFS1_HUMAN,K81R,0.039,-,-,-
WFS1_HUMAN,V106M,0.311,-,-,-
WFS1_HUMAN,G115S,0.047,-,-,-
WFS1_HUMAN,T117A,0.029,-,-,-
WFS1_HUMAN,T117K,0.099,-,-,-
WFS1_HUMAN,T117R,0.108,-,-,-
WFS1_HUMAN,S123A,0.183,-,-,-
WFS1_HUMAN,V131I,0.031,-,-,-
WFS1_HUMAN,L145A,0.881,Altered Disordered interface (Pr = 0.27 | P = 0.01); Altered Coiled coil (Pr = 0.25 | P = 0.02); Altered Stability (Pr = 0.21 | P = 0.01); Loss of Proteolytic cleavage at R147 (Pr = 0.11 | P = 0.04); Gain of Disulfide linkage at C148 (Pr = 0.10 | P = 0.05), ELME000012|ELME000149,-
WFS1_HUMAN,R153K,0.054,-,-,-
WFS1_HUMAN,I489L,0.092,-,-,-
WFS1_HUMAN,V491M,0.174,-,-,-
WFS1_HUMAN,F564C,0.642,Altered Transmembrane protein (Pr = 0.30 | P = 1.6e-04); Altered Ordered interface (Pr = 0.26 | P = 0.01), ELME000120|ELME000182|ELME000328,-
WFS1_HUMAN,T590V,0.060,-,-,-
WFS1_HUMAN,V601M,0.072,-,-,-
WFS1_HUMAN,H692P,0.936,Altered Metal binding (Pr = 0.68 | P = 1.2e-03); Altered Ordered interface (Pr = 0.30 | P = 0.02); Altered Transmembrane protein (Pr = 0.29 | P = 3.5e-04); Loss of Helix (Pr = 0.27 | P = 0.05); Gain of Allosteric site at C690 (Pr = 0.21 | P = 0.03); Gain of Disulfide linkage at C690 (Pr = 0.20 | P = 0.02); Gain of Catalytic site at C690 (Pr = 0.16 | P = 0.02), ELME000064|ELME000136|ELME000159|PS00006,-
WFS1_HUMAN,G728S,0.478,-,-,-
WFS1_HUMAN,G789S,0.101,-,-,-
WFS1_HUMAN,S792G,0.045,-,-,-
WFS1_HUMAN,V875I,0.065,-,-,-
WFS1_HUMAN,M518K,0.915,Altered Transmembrane protein (Pr = 0.32 | P = 7.8e-05); Gain of Pyrrolidone carboxylic acid at Q520 (Pr = 0.07 | P = 0.02), ELME000102,-
WFS1_HUMAN,L200P,0.844,Gain of Intrinsic disorder (Pr = 0.38 | P = 0.01); Altered Stability (Pr = 0.25 | P = 8.0e-03); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), ELME000155,-
WFS1_HUMAN,S236R,0.281,-,-,-
WFS1_HUMAN,A684T,0.774,Loss of Helix (Pr = 0.29 | P = 0.01); Altered Transmembrane protein (Pr = 0.26 | P = 8.4e-04); Gain of N-linked glycosylation at N682 (Pr = 0.05 | P = 0.02), ELME000052|ELME000070|ELME000202|ELME000336|PS00001,-
WFS1_HUMAN,V624A,0.137,-,-,-
WFS1_HUMAN,R228H,0.174,-,-,-
WFS1_HUMAN,L543R,0.855,Altered Ordered interface (Pr = 0.24 | P = 0.03); Altered Transmembrane protein (Pr = 0.14 | P = 0.02), ELME000147|ELME000313|ELME000335,-
WFS1_HUMAN,T156M,0.436,-,-,-
WFS1_HUMAN,L723P,0.949,Altered Transmembrane protein (Pr = 0.39 | P = 9.7e-06); Altered Ordered interface (Pr = 0.39 | P = 1.3e-03); Loss of Helix (Pr = 0.30 | P = 8.1e-03); Gain of Relative solvent accessibility (Pr = 0.28 | P = 0.01); Altered Disordered interface (Pr = 0.27 | P = 0.04); Altered Metal binding (Pr = 0.25 | P = 0.01), None,-
WFS1_HUMAN,H860D,0.538,Altered Transmembrane protein (Pr = 0.27 | P = 7.3e-04); Altered Stability (Pr = 0.10 | P = 0.04), ELME000102|ELME000108|ELME000146|ELME000220|PS00006,-
WFS1_HUMAN,R732C,0.770,Altered Metal binding (Pr = 0.37 | P = 0.01); Altered Transmembrane protein (Pr = 0.36 | P = 1.9e-05); Altered Ordered interface (Pr = 0.25 | P = 0.02); Loss of Disulfide linkage at C733 (Pr = 0.18 | P = 0.03), ELME000106,-
WFS1_HUMAN,R383C,0.465,-,-,-
WFS1_HUMAN,C690Y,0.961,Altered Metal binding (Pr = 0.49 | P = 4.0e-03); Altered Ordered interface (Pr = 0.33 | P = 8.6e-03); Loss of Helix (Pr = 0.29 | P = 0.02); Gain of Catalytic site at C690 (Pr = 0.28 | P = 2.4e-03); Altered Transmembrane protein (Pr = 0.26 | P = 9.9e-04); Loss of Disulfide linkage at C690 (Pr = 0.23 | P = 0.01), ELME000020|ELME000052|ELME000064|ELME000120,-
WFS1_HUMAN,R629W,0.417,-,-,-
WFS1_HUMAN,N714T,0.875,Loss of Relative solvent accessibility (Pr = 0.31 | P = 6.9e-03); Altered Ordered interface (Pr = 0.28 | P = 0.04); Altered Transmembrane protein (Pr = 0.25 | P = 1.1e-03); Altered Metal binding (Pr = 0.22 | P = 4.5e-03); Altered DNA binding (Pr = 0.21 | P = 0.02), ELME000053|ELME000064|ELME000085|ELME000147|ELME000220|ELME000321|PS00006,-
WFS1_HUMAN,T665P,0.802,Gain of Loop (Pr = 0.27 | P = 0.04); Gain of N-linked glycosylation at N661 (Pr = 0.27 | P = 3.6e-04); Altered Ordered interface (Pr = 0.26 | P = 0.02); Altered Transmembrane protein (Pr = 0.23 | P = 2.2e-03); Loss of Sulfation at Y660 (Pr = 0.03 | P = 0.02), ELME000063|ELME000070,-
WFS1_HUMAN,L402P,0.906,Altered Ordered interface (Pr = 0.26 | P = 0.01); Altered Transmembrane protein (Pr = 0.17 | P = 9.6e-03), None,-
WFS1_HUMAN,G695V,0.933,Altered Ordered interface (Pr = 0.35 | P = 3.8e-03); Altered Transmembrane protein (Pr = 0.29 | P = 3.8e-04); Altered Metal binding (Pr = 0.28 | P = 0.02); Gain of Allosteric site at W700 (Pr = 0.28 | P = 3.3e-03); Altered DNA binding (Pr = 0.21 | P = 0.02); Loss of Disulfide linkage at C690 (Pr = 0.18 | P = 0.03); Loss of Catalytic site at C690 (Pr = 0.13 | P = 0.03), ELME000137,-
WFS1_HUMAN,D797V,0.588,Loss of Intrinsic disorder (Pr = 0.43 | P = 0.02); Loss of B-factor (Pr = 0.27 | P = 0.03); Loss of Loop (Pr = 0.27 | P = 0.04); Altered Metal binding (Pr = 0.19 | P = 0.05); Loss of Ubiquitylation at K800 (Pr = 0.16 | P = 0.04); Altered Transmembrane protein (Pr = 0.14 | P = 0.02), ELME000052,-
WFS1_HUMAN,E864K,0.757,Loss of Strand (Pr = 0.28 | P = 0.01); Gain of Helix (Pr = 0.27 | P = 0.03); Altered Transmembrane protein (Pr = 0.19 | P = 5.8e-03); Altered Stability (Pr = 0.09 | P = 0.05), ELME000002,-
WFS1_HUMAN,P607R,0.770,Altered Disordered interface (Pr = 0.39 | P = 3.8e-03); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), ELME000106|ELME000146|ELME000335|ELME000337|PS00005,-
WFS1_HUMAN,G831D,0.828,Altered Transmembrane protein (Pr = 0.31 | P = 1.3e-04), ELME000220,-
WFS1_HUMAN,R611C,0.383,-,-,-
WFS1_HUMAN,C690G,0.962,Altered Metal binding (Pr = 0.45 | P = 5.1e-03); Altered Ordered interface (Pr = 0.28 | P = 0.05); Loss of Helix (Pr = 0.28 | P = 0.03); Altered Transmembrane protein (Pr = 0.26 | P = 9.9e-04); Gain of Relative solvent accessibility (Pr = 0.25 | P = 0.03); Loss of Disulfide linkage at C690 (Pr = 0.23 | P = 0.01); Gain of Catalytic site at C690 (Pr = 0.14 | P = 0.03); Altered Stability (Pr = 0.09 | P = 0.05), ELME000052|ELME000064,-
WFS1_HUMAN,R703H,0.543,Altered Transmembrane protein (Pr = 0.28 | P = 4.6e-04); Altered Ordered interface (Pr = 0.28 | P = 0.05); Altered DNA binding (Pr = 0.27 | P = 3.5e-03); Loss of Allosteric site at W700 (Pr = 0.26 | P = 0.01); Gain of Acetylation at K705 (Pr = 0.19 | P = 0.05), ELME000080|PS00005,-
WFS1_HUMAN,D211N,0.263,-,-,-
WFS1_HUMAN,P838L,0.775,Altered Transmembrane protein (Pr = 0.35 | P = 2.4e-05), ELME000106|ELME000137,-
WFS1_HUMAN,A716T,0.420,-,-,-
WFS1_HUMAN,A616S,0.081,-,-,-
WFS1_HUMAN,V779G,0.841,Altered Stability (Pr = 0.52 | P = 1.5e-03); Gain of Intrinsic disorder (Pr = 0.37 | P = 0.01); Altered Transmembrane protein (Pr = 0.11 | P = 0.03), ELME000147|ELME000155|ELME000233|ELME000336,-
WFS1_HUMAN,L757I,0.102,-,-,-
WFS1_HUMAN,G107E,0.767,Loss of Acetylation at K108 (Pr = 0.28 | P = 6.1e-03), ELME000064|ELME000220|PS00006,-
WFS1_HUMAN,A677T,0.573,Altered Transmembrane protein (Pr = 0.30 | P = 1.8e-04); Altered Ordered interface (Pr = 0.25 | P = 0.02); Loss of Disulfide linkage at C673 (Pr = 0.18 | P = 0.03), ELME000053|ELME000064|ELME000220|PS00005|PS00006,-
